

Contents

| | | | |
|--|------|--|----|
| List of participants | xi | Other and emerging imaging techniques | 34 |
| Preface | xiii | Digital mammography | 34 |
| 1. Breast cancer and screening | | Ultrasonography | 36 |
| The world-wide burden of breast cancer | 1 | Magnetic resonance imaging | 36 |
| Breast cancer biology, pathology and natural history as related to screening | 4 | Positron emission tomography | 37 |
| Barriers to understanding of early cancers | 5 | Scintimammography | 38 |
| Benign breast disease | 5 | Electrical impedance imaging | 38 |
| Carcinoma in situ | 6 | Other techniques | 38 |
| Invasive carcinoma | 9 | Clinical breast examination | 39 |
| Can a patient be 'cured' of breast cancer ? | 16 | Technique | 39 |
| Diagnosis and treatment | 16 | Training | 41 |
| Screening for breast cancer: Conceptual considerations | 17 | Maintenance of standards | 42 |
| General definitions | 18 | Costs and potential harms | 43 |
| Positive predictive value, specificity and the issue of over-diagnosis | 20 | Other issues | 43 |
| Cancers detected at screening, interval cancers and distribution of lead time and sojourn time | 20 | Breast self-examination | 43 |
| Period screening: Length bias and the unbiased set | 20 | Technique | 43 |
| A more complex view of cancer | 21 | Training | 44 |
| Evaluation of screening for breast cancer | 22 | Maintenance of standards | 45 |
| 2. Screening techniques | | Mechanisms for improving breast self-examination | 45 |
| Screening mammography | 25 | Costs and potential harms | 46 |
| X-ray equipment | 25 | Other issues | 46 |
| Radiation dose | 28 | 3. Use of breast cancer screening | |
| Quality control | 28 | Delivery and uptake of screening | 47 |
| Sensitivity and specificity | 28 | Europe | 48 |
| Host factors that affect sensitivity | 32 | Americas | 54 |
| One versus two views | 33 | Oceania and Asia | 64 |
| Double reading | 34 | Behavioural factors and the longer-term success of screening | 72 |
| | | Information and understanding | 72 |
| | | Psychological consequences of participation in screening | 74 |
| | | Encouraging participation in screening | 74 |

4. Efficacy of screening

Methodological and analytical issues in

| | |
|--|----|
| assessing efficacy | 87 |
| Issues in evaluating the efficacy of screening | 87 |
| Use of randomized controlled trials in evaluation of screening | 88 |
| Use of cohort (observational) and case-control studies in evaluating screening | 91 |

Efficacy of screening by conventional

| | |
|--|-----|
| mammography | 91 |
| Randomized trials | 91 |
| Cohort and nested case-control studies | 101 |
| Quasi-experimental study | 102 |

Efficacy of screening by clinical breast examination

102

Efficacy of screening by breast self-

| | |
|---|-----|
| examination | 107 |
| Randomized trials | 107 |
| Cohort studies | 108 |
| Case-control studies | 110 |
| Studies of survival | 110 |
| Studies of extent of disease at diagnosis | 111 |

Efficacy of screening women at high risk

| | |
|----------------------------------|-----|
| Radiation sensitivity | 115 |
| Tumour factors | 115 |
| Family history | 115 |
| BRCA1 and BRCA2 | 116 |
| Magnetic resonance imaging | 117 |

5. Effectiveness of screening

Has screening been implemented in accordance with the results of screening trials?

119

| | |
|-----------------------------------|-----|
| Methods of invitation | 119 |
| Screening processes | 119 |
| Age range | 120 |
| Screening interval | 120 |
| Mammography | 120 |
| Clinical breast examination | 121 |
| Breast self examination | 121 |

Indicators for monitoring and evaluating the effectiveness of screening programmes

| | |
|---|-----|
| Origins of indicators of effectiveness of screening | 122 |
| Performance indicators | 123 |
| Mortality from and screening for breast cancer in different countries | 129 |
| Alternative measures of effect on mortality | 132 |
| Balance between false-positive and false-negative results | 133 |
| Conclusion | 134 |

Hazards (risks) of screening

| | |
|--|-----|
| Occurrence and consequences of false-positive results in mammography | 135 |
| Overdiagnosis | 144 |
| Reservoir of potentially detectable breast cancer | 147 |
| Ductal carcinoma in situ | 148 |
| Early mortality from breast cancer | 150 |
| Risk for breast cancer induced by radiation | 150 |

6. Cost-effectiveness of population-based breast cancer screening

Cost-effectiveness analysis: What and why?

| | |
|-----------------------------------|-----|
| Published analyses | 157 |
| Application of strict rules | 158 |

Elements of cost-effectiveness

| | |
|-------------------------------------|-----|
| Effectiveness | 158 |
| Unfavourable effects | 159 |
| Costs | 161 |
| Discounting effects and costs | 162 |

Modelling for policy decisions

| | |
|---|-----|
| Policy decisions on age categories to be screened | 164 |
| Policy decisions on screening interval | 164 |
| Policy decisions on high-risk groups | 165 |
| Policy decisions on recall or referral | 165 |

Participation

165

Cost-effectiveness in practice

| | |
|--------------------------|-----|
| Quality of life | 166 |
| Cost | 168 |
| Cost-effectiveness | 168 |

| | | | |
|---|-----|---|-----|
| Limitations of cost-effectiveness analysis | 168 | Overall evaluation | 179 |
| Practical limitations | 168 | Effect of screening with mammography on mortality from breast cancer | 179 |
| Gaps in knowledge | 169 | Influence of inter-screening interval on effect of screening by mammography | 179 |
| New developments | 169 | Effect of breast screening by clinical breast examination on mortality from breast cancer | 180 |
| 7. Summary | | Effect of breast screening by breast self-examination on mortality from breast cancer | 180 |
| Breast cancer and screening | 171 | Effectiveness in practice of breast cancer screening with mammography | 180 |
| World-wide burden | 171 | Adverse effects of breast screening | |
| Biology, pathology and natural history | 171 | Cost-effectiveness of a programme of screening with mammography | 181 |
| Conceptual considerations | 171 | Implications for public health | 181 |
| Screening techniques | 171 | 9. Recommendations | |
| Screening mammography | 171 | Research recommendations | 183 |
| Other and emerging imaging techniques | 172 | Improving conventional mammography | 183 |
| Clinical breast examination | 172 | Implementing mammographic screening programmes | 183 |
| Breast self-examination | 172 | Accuracy of mammographic screening | 183 |
| Use of breast cancer screening | 172 | Clinical breast examination | 183 |
| Delivery and uptake of screening | 172 | Breast self-examination | 184 |
| Behavioural considerations in screening participation | 173 | Consequences of diagnosis of breast cancer | 184 |
| Efficacy of screening | 173 | Biology of breast tumours in relation to screening | 184 |
| Methodological and analytical issues in assessing efficacy | 173 | New techniques | 185 |
| Conventional screening mammography | 173 | Women at high risk | 185 |
| Clinical breast examination | 174 | Public health recommendations | 186 |
| Breast self-examination | 174 | Information systems | 186 |
| Women at high-risk | 174 | Implementation of mammographic screening programmes | 186 |
| Effectiveness of population-based screening . . | 175 | References | 187 |
| Implementation of population-based screening in accordance with results of screening trials | 175 | Glossary | 219 |
| Indicators of the effectiveness of population-based screening programmes | 175 | Working Procedures | 223 |
| Hazards of screening | 176 | Sources of figures | 229 |
| Cost-effectiveness of population-based screening | 176 | | |
| 8. Evaluation | | | |
| Evaluation of the efficacy of breast cancer screening | 179 | | |